Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA

Journal of Neuro-Oncology

Volumn 103, Issue 2, 2011, Pages 361-370

  Stummer, Walter ^a   Nestler, Ulf ^b   Stockhammer, Florian ^c   Krex, Dietmar ^d   Kern, Bodo C ^e   Mehdorn, Hubert M ^f   Vince, Giles H ^g   Pichlmeier, Uwe ^h  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e BG KLINIKEN BERGMANNSTROST   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h MEDAC GMBH   (Germany)

Author keywords

5 ALA; Concomitant radiochemotherapy; Elderly; Fluorescence guided resection; Glioblastoma

Indexed keywords

AMINOLEVULINIC ACID; TEMOZOLOMIDE;

ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG SAFETY; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FLUORESCENCE IMAGING; GASTROINTESTINAL DISEASE; GERIATRIC PATIENT; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SURGICAL INFECTION; SURGICAL INJURY; SURGICAL RISK; SURVIVAL RATE; VASCULAR DISEASE; WOUND COMPLICATION;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PHOTOSENSITIZING AGENTS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 79958734296     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0400-9     Document Type: Article

References (21)

1. Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401
2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
3. Surawicz TS, McCarthy BJ, Kupelian V et al (1999) Descriptive epidemiology of primary brain and CNS tumors. Results from the central brain tumor registry of the United States, 1990-1994. Neurooncology 1:14-25
4. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79-88 (Pubitemid 36422560)
5. Laws ER, Parney IF, Huang W et al (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J Neurosurg 99:467-473 (Pubitemid 37040405)
6. Kita D, Ciernik IF, Vaccarella S et al (2009) Age as predictive factor in glioblastomas: population-based study. Neuroepidemiology 33:17-22
7. Iwamoto FM, Reiner AS, Panageas KS et al (2008) Patterns of care in elderly glioblastoma patients. Ann Neurol 64:628-634
8. Stummer W, Kamp MA (2009) The importance of surgical resection in malignant glioma. Curr Opin Neurol 22:645-649
9. Chang SM, Parney IF, McDermott M et al (2003) Glioma outcomes investigators. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the glioma outcome project. J Neurosurg 98:1175-1181 (Pubitemid 36617917)
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC (2005) Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
11. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in gtlioablastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
12. Vuorinen V, Hinkka S, Farkkila M et al (2003) Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 145:5-10 (Pubitemid 36174074)
13. Kelly PJ, Hunt C (1994) The limited value of cytoreductive therapy in elderly patients with malignant glioms. Neurosurgery 34:62-66
14. Ampil F, Fowler M, Kookmin K (1992) Intracranial astrocytoma in elderly patients. J Neuro-Oncol 12:125-130
15. Brandes AA, Vastola F, Basso U et al (2003) A prospective study on glioblastoma in the elderly. Cancer 97:657-662 (Pubitemid 36125843)
16. Iwamoto FM, Cooper AR, Reiner AS et al (2009) Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer 115:3758-3766
17. Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067 (Pubitemid 30035956)
18. Gross CP, Herrin J, Wong N et al (2005) Enrolling older persons in cancer trials: the effect of socio-demographic, protocol, and recruitment center characteristics. J Clin Oncol 23:4755-4763 (Pubitemid 46224079)
19. Yee KW, Pater JL, Pho L et al (2003) Enrollment of older patients in cancer treatment trials in Canada: why age is a barrier? J Clin Oncol 21:1618-1623 (Pubitemid 46594117)
20. Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512-3518
21. Minniti G, De Sanctis V, Muni R et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97-103